Redox nanomedicine ameliorates chronic kidney disease (CKD) by mitochondrial reconditioning in mice.

ABSTRACT: Targeting reactive oxygen species (ROS) while maintaining cellular redox signaling is crucial in the development of redox medicine as the origin of several prevailing diseases including chronic kidney disease (CKD) is linked to ROS imbalance and associated mitochondrial dysfunction. Here, we have shown that a potential nanomedicine comprising of Mn₃O₄ nanoparticles duly functionalized with biocompatible ligand citrate (C-Mn₃O₄ NPs) can maintain cellular redox balance in an animal model of oxidative injury. We developed a cisplatin-induced CKD model in C57BL/6j mice with severe mitochondrial dysfunction and oxidative distress leading to the pathogenesis. Four weeks of treatment with C-Mn₃O₄ NPs restored renal function, preser

SUBMITTER: Adhikari A 

PROVIDER: S-EPMC8390471 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature